Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...

Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

Nuvation Bio has secured $250m in non-dilutive financing from Sagard, aimed at funding the commercialisation of taletrectinib ...

HYDERABAD: VeGen Labs LLP, a biotech startup incubated at ASPIRE-TBI and ASPIRE-BioNEST, University of Hyderabad (UoH), has been awarded Rs 3.765 crore funding ...